AR120171A1 - Composición farmacéutica de vector de virus adenoasociado y métodos - Google Patents
Composición farmacéutica de vector de virus adenoasociado y métodosInfo
- Publication number
- AR120171A1 AR120171A1 ARP200102778A ARP200102778A AR120171A1 AR 120171 A1 AR120171 A1 AR 120171A1 AR P200102778 A ARP200102778 A AR P200102778A AR P200102778 A ARP200102778 A AR P200102778A AR 120171 A1 AR120171 A1 AR 120171A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- associated virus
- adeno
- methods
- virus vector
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962911968P | 2019-10-07 | 2019-10-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR120171A1 true AR120171A1 (es) | 2022-02-02 |
Family
ID=73131798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200102778A AR120171A1 (es) | 2019-10-07 | 2020-10-07 | Composición farmacéutica de vector de virus adenoasociado y métodos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240108669A1 (OSRAM) |
| EP (1) | EP4041292A1 (OSRAM) |
| JP (1) | JP2022552262A (OSRAM) |
| KR (1) | KR20220081365A (OSRAM) |
| CN (3) | CN114728049A (OSRAM) |
| AR (1) | AR120171A1 (OSRAM) |
| AU (1) | AU2020362119A1 (OSRAM) |
| BR (1) | BR112022006718A2 (OSRAM) |
| CA (1) | CA3156984A1 (OSRAM) |
| IL (1) | IL291930A (OSRAM) |
| MX (1) | MX2022004146A (OSRAM) |
| TW (2) | TW202525312A (OSRAM) |
| WO (1) | WO2021071835A1 (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020012336A2 (pt) | 2017-12-19 | 2021-03-30 | Akouos, Inc. | Administração de anticorpos terapêuticos mediada por aav para o ouvido interno |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023006471A (es) * | 2020-12-18 | 2023-08-11 | Sangamo Therapeutics Inc | Composiciones farmaceuticas mejoradas que contienen vector viral adenoasociado. |
| JP2025509566A (ja) * | 2022-03-14 | 2025-04-11 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ａａｖ医薬製品の凍結乾燥製剤 |
| TW202404651A (zh) * | 2022-04-06 | 2024-02-01 | 美商銳進科斯生物股份有限公司 | 用於脈絡膜上投與之調配物諸如形成聚集體之調配物 |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| CN115554418B (zh) * | 2022-11-22 | 2023-04-14 | 四川至善唯新生物科技有限公司 | 一种重组腺相关病毒载体的药物组合物及其用途 |
| CN115869425B (zh) * | 2022-12-12 | 2024-08-20 | 北京生物制品研究所有限责任公司 | 一种aav眼用注射液及其制备方法和应用 |
| IL321632A (en) * | 2022-12-23 | 2025-08-01 | Spark Therapeutics Inc | Adeno-associated virus formulations |
| WO2024220966A1 (en) * | 2023-04-21 | 2024-10-24 | The Regents Of The University Of California | Novel glycan compounds for age-related macular degeneration |
| AU2024271004A1 (en) | 2023-05-16 | 2026-01-15 | Regenxbio Inc. | Vectorized anti-complement antibodies and administration thereof |
| TW202508610A (zh) * | 2023-08-23 | 2025-03-01 | 大陸商上海瑞宏迪醫藥有限公司 | 醫藥組成物及其用途 |
| CN119015447A (zh) * | 2023-09-01 | 2024-11-26 | 康霖生物科技（杭州）有限公司 | 一种缓冲系统及其相应液体制剂及其用途 |
| CN119769462A (zh) * | 2023-10-07 | 2025-04-08 | 陈国韬 | 一种非器质性（心理性）勃起功能障碍大鼠模型的构建方法 |
| WO2025113676A1 (en) * | 2023-11-29 | 2025-06-05 | Neuexcell Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treating stroke in primates |
| WO2025217230A1 (en) | 2024-04-08 | 2025-10-16 | Regenxbio Inc. | Vectorized anti-complement antibodies and complement agents and administration thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1978095A1 (en) | 1993-02-12 | 2008-10-08 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptor proteins for controlling signal transduction and ligands binding thereto |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| WO1996041865A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamcycin-based regulation of biological events |
| AU9036198A (en) | 1997-08-26 | 1999-03-16 | Ariad Gene Therapeutics, Inc. | Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain |
| EP1003886A1 (en) | 1997-08-27 | 2000-05-31 | Ariad Gene Therapeutics, Inc. | Chimeric transcriptional activators and compositions and uses related thereto |
| CA2318402A1 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| EP1053241A1 (en) | 1998-02-13 | 2000-11-22 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| EP2369002A1 (en) | 1999-08-09 | 2011-09-28 | Targeted Genetics Corporation | Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms intrastrand base pairs |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| SG10202108118RA (en) | 2001-11-13 | 2021-08-30 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2975413T3 (es) | 2001-12-17 | 2024-07-05 | Univ Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas |
| HUE054805T2 (hu) | 2003-09-30 | 2021-09-28 | Univ Pennsylvania | Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik |
| BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| EP3085389A1 (en) | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| WO2006132118A1 (ja) | 2005-06-09 | 2006-12-14 | Matsushita Electric Industrial Co., Ltd. | 振幅誤差補償装置及び直交度誤差補償装置 |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| CN107828820B (zh) | 2010-10-27 | 2022-06-07 | 学校法人自治医科大学 | 用于向神经系统细胞导入基因的腺相关病毒粒子 |
| US9409953B2 (en) | 2011-02-10 | 2016-08-09 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| CN107012171B (zh) | 2011-04-22 | 2021-07-13 | 加利福尼亚大学董事会 | 具有变异衣壳的腺相关病毒病毒体及其使用方法 |
| EP3147295B2 (en) | 2011-08-24 | 2023-11-22 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| CA2905952A1 (en) | 2013-03-13 | 2014-10-02 | The Children's Hospital Of Philadelphia | Adeno-associated virus vectors and methods of use thereof |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| NZ718926A (en) | 2013-10-11 | 2021-12-24 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| WO2017180936A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| SG11201808440YA (en) | 2016-04-15 | 2018-10-30 | Regenxbio Inc | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| DK3472317T3 (da) * | 2016-06-16 | 2022-05-23 | Adverum Biotechnologies Inc | Sammensætninger og fremgangsmåder til reduktion af okulær vaskularisation |
| PT3534922T (pt) * | 2016-11-04 | 2024-06-07 | Takeda Pharmaceuticals Co | Formulações de vírus adenoassociado |
| TWI832036B (zh) * | 2017-08-03 | 2024-02-11 | 美商航海家醫療公司 | 用於aav之遞送之組合物及方法 |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| IL327339A (en) * | 2018-11-14 | 2026-05-01 | Regenxbio Inc | Gene therapy for neural ceroid lipofuscinosis |
-
2020
- 2020-10-06 CN CN202080079668.3A patent/CN114728049A/zh active Pending
- 2020-10-06 US US17/766,941 patent/US20240108669A1/en active Pending
- 2020-10-06 JP JP2022521243A patent/JP2022552262A/ja active Pending
- 2020-10-06 MX MX2022004146A patent/MX2022004146A/es unknown
- 2020-10-06 KR KR1020227015158A patent/KR20220081365A/ko active Pending
- 2020-10-06 EP EP20801425.8A patent/EP4041292A1/en active Pending
- 2020-10-06 CN CN202610171188.9A patent/CN122005864A/zh active Pending
- 2020-10-06 IL IL291930A patent/IL291930A/en unknown
- 2020-10-06 BR BR112022006718A patent/BR112022006718A2/pt unknown
- 2020-10-06 WO PCT/US2020/054400 patent/WO2021071835A1/en not_active Ceased
- 2020-10-06 AU AU2020362119A patent/AU2020362119A1/en active Pending
- 2020-10-06 CA CA3156984A patent/CA3156984A1/en active Pending
- 2020-10-06 CN CN202610160081.4A patent/CN122005863A/zh active Pending
- 2020-10-07 AR ARP200102778A patent/AR120171A1/es unknown
- 2020-10-07 TW TW114110012A patent/TW202525312A/zh unknown
- 2020-10-07 TW TW109134835A patent/TWI879814B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20240108669A1 (en) | 2024-04-04 |
| CN114728049A (zh) | 2022-07-08 |
| CA3156984A1 (en) | 2021-04-15 |
| BR112022006718A2 (pt) | 2022-07-12 |
| JP2022552262A (ja) | 2022-12-15 |
| IL291930A (en) | 2022-06-01 |
| CN122005863A (zh) | 2026-05-12 |
| MX2022004146A (es) | 2022-09-19 |
| WO2021071835A1 (en) | 2021-04-15 |
| TWI879814B (zh) | 2025-04-11 |
| AU2020362119A1 (en) | 2022-05-26 |
| TW202126319A (zh) | 2021-07-16 |
| TW202525312A (zh) | 2025-07-01 |
| EP4041292A1 (en) | 2022-08-17 |
| CN122005864A (zh) | 2026-05-12 |
| KR20220081365A (ko) | 2022-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241346A1 (es) | Vectores del factor viii del virus adeno-asociado, particulas viricas asociadas y formulaciones que los comprenden | |
| MX2022004146A (es) | Composición farmacéutica de vector de virus adenoasociado y métodos. | |
| EP4360652A3 (en) | Adeno-associated virus formulations | |
| AR127361A2 (es) | Composición farmacéutica de partículas de lipoplejos y arn, composición acuosa y método de preparación | |
| CO2017013287A2 (es) | Composiciones que comprenden una cepa bacteriana del género roseburia | |
| EA201791936A1 (ru) | Рекомбинантные конструкции glut1 аденоассоциированного вирусного вектора и способы восстановления экспрессии glut1 на их основе | |
| CO2017013231A2 (es) | Composiciones que comprenden una cepa bacteriana del género parabacteroides | |
| CO2020013552A2 (es) | Formulación de anticuerpos | |
| MX2018013215A (es) | Composicion farmaceutica. | |
| AR100268A1 (es) | Formulación líquida que comprende compuesto neutralizante de gm-csf | |
| BR112018075785A2 (pt) | formulação de vacina para o hiv | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| SA521421715B1 (ar) | تركيبات سيماجلوتيد ثابتة واستخداماتها | |
| AR108631A1 (es) | Formulación de neurotoxinas | |
| AR116876A1 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
| AR095527A1 (es) | Formulaciones de polipéptido fc-factor ix | |
| MX2023006471A (es) | Composiciones farmaceuticas mejoradas que contienen vector viral adenoasociado. | |
| PE20220570A1 (es) | Anticuerpo anti-epha4 humano | |
| AR114389A1 (es) | Composición farmacéutica que comprende péptido tipo apl | |
| AR126417A1 (es) | Composición farmacéutica de virus no encapsulado | |
| MX2023011087A (es) | Composicion farmaceutica acuosa o composicion farmaceutica liofilizada estable. | |
| CO2020001322A2 (es) | Tratamiento de hemorragia gastrointestinal en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante | |
| MX421763B (es) | Metodos y composiciones que comprenden proteina d tensoactiva (sp-d) | |
| BR112021021917A2 (pt) | Composição de reciclagem eutética | |
| AR123998A1 (es) | Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden |